Gilron I, Wajsbrot D, Therrien F, Lemay J.<\/p>\n\n\n\n
*Departments of Anesthesiology and Pharmacology and Toxicology, Queen\u2019s University, Kingston, Ontario \u2021Pfizer Canada Inc, Montreal, Canada \u2020Pfizer Global Pharmaceuticals, New York, NY.
Abstract<\/p>\n\n\n\n
OBJECTIVES<\/strong>: To date, published neuropathic pain randomized controlled trials of pregabalin have involved primarily diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). This multicenter trial evaluated pregabalin in a broader range of neuropathic pain etiologies.<\/p>\n\n\n\n METHODS:<\/strong> In this enriched enrollment randomized withdrawal trial, 256 patients received single blind, flexible dose pregabalin for 4 weeks; stable concomitant analgesics were allowed. One hundred sixty-five (65%) had a \u226530% pain improvement and 157 were randomized and treated, double blind, to either continue pregabalin (n=80) or to receive placebo (n=77) for 5 weeks.<\/p>\n\n\n\n RESULTS<\/strong>: Of the single blind responders randomized, 81% on placebo and 86% on pregabalin completed the double-blind phase. At the double-blind endpoint, mean (SD) pain scores were 2.9 (1.9) in the pregabalin group and 3.5 (1.7) in the placebo group (P=0.002). These modest yet significant pregabalin-placebo differences were observed within each of the subgroups of patients with a diagnosis of either DPN or PHN (P=0.03), and with other diagnoses (P=0.02). Significant differences were also observed in sleep interference, Hospital Anxiety and Depression Scale Anxiety and Depression subscales, and other secondary measures. In total, 28 out of 80 (35.0%) in the pregabalin group and 28 out of 77 (36.4%) in the placebo group had either a meaningful increase in pain or discontinued the double-blind phase. Adverse events were consistent with the known tolerability profile of pregabalin and led to discontinuation of 9 during the single-blind phase, and 5 and 2 patients from the placebo and pregabalin groups, respectively.<\/p>\n\n\n\n DISCUSSION<\/strong>: These results support previous evidence of pregabalin efficacy but further demonstrate efficacy and tolerability in a broader range of peripheral neuropathic pain conditions beyond just DPN and PHN.<\/p>\n\n\n\n PMID: 21178603 [PubMed \u2013 as supplied by publisher]<\/p>\n\n\n\n LinkOut \u2013 more resources<\/p>\n","protected":false},"excerpt":{"rendered":" Gilron I, Wajsbrot D, Therrien F, Lemay J. *Departments of Anesthesiology and Pharmacology and Toxicology, Queen\u2019s University, Kingston, Ontario \u2021Pfizer Canada Inc, Montreal, Canada \u2020Pfizer Global Pharmaceuticals, New York, NY.Abstract OBJECTIVES: To date, published neuropathic pain randomized controlled trials of pregabalin have involved primarily diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). This multicenter trial […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[186,191],"tags":[],"class_list":["post-5803","post","type-post","status-publish","format-standard","hentry","category-186","category-191"],"_links":{"self":[{"href":"https:\/\/e-algos.com\/el\/wp-json\/wp\/v2\/posts\/5803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/e-algos.com\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/e-algos.com\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/e-algos.com\/el\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/e-algos.com\/el\/wp-json\/wp\/v2\/comments?post=5803"}],"version-history":[{"count":1,"href":"https:\/\/e-algos.com\/el\/wp-json\/wp\/v2\/posts\/5803\/revisions"}],"predecessor-version":[{"id":5804,"href":"https:\/\/e-algos.com\/el\/wp-json\/wp\/v2\/posts\/5803\/revisions\/5804"}],"wp:attachment":[{"href":"https:\/\/e-algos.com\/el\/wp-json\/wp\/v2\/media?parent=5803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/e-algos.com\/el\/wp-json\/wp\/v2\/categories?post=5803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/e-algos.com\/el\/wp-json\/wp\/v2\/tags?post=5803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}